NEW YORK (GenomeWeb News) – The National Institutes of Health has awarded Phoenix S&T a Phase II Small Business Innovation Research grant to develop a prototype microfluidics device to separate glycoproteins that may be used as biomarkers for cancer and other diseases, the company said last week.
Phoenix S&T said the award is worth as much as $1.2 million over three years.
The company, based in Elkton, Md., said it will use the funds to continue developing a microfluidic chromatographic device that uses nanoparticles as a medium for quickly separating complex proteins. The device will interface with nanospray mass spectrometry to detect and identify proteins, Phoenix S&T added.
Company president Sau Lan Staats said Phoenix S&T's goal is to make the separation of post-translationally modified proteins "routine and high throughput," which is expected to increase efficiency in many applications.